Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.

Abstract

The results of the RV144 vaccine clinical trial showed a correlation between high level of anti-V1V2 antibodies (Abs) and a decreased risk of acquiring HIV-1 infection. This turned the focus of HIV vaccine design to the induction of elevated levels of anti-V2 Abs to increase vaccine efficacy. In plasma samples from HIV-1 infected Cameroonian individuals, we observed broad variations in levels of anti-V2 Abs, and 6 of the 79 plasma samples tested longitudinally displayed substantial deficiency of V2 Abs. Sequence analysis of the V2 region from plasma viruses and multivariate analyses of V2 characteristics showed a significant difference in several features between V2-deficient and V2-reactive plasma Abs. These results suggest that HIV vaccine immunogens containing a shorter V2 region with fewer glycosylation sites and higher electrostatic charges can be beneficial for induction of a higher level of anti-V2 Abs and thus contribute to HIV vaccine efficacy.

• Authors: Lily Liu, Liuzhe Li, Aubin Nanfack, Luzia M Mayr, Sonal Soni, Adam Kohutnicki, Lucy Agyingi, Xiao-Hong Wang, Michael Tuen, Yongzhao Shao, Maxim Totrov, Susan Zolla-Pazner, Xian-Peng Kong, Ralf Duerr, Miroslaw K Gorny
• Journal: Virology (Virology) Vol. 529 Pg. 57-64 (03 2019) ISSN: 1096-0341 [Electronic] United States
• PMID: 30665098 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• AIDS Vaccines
• HIV Antibodies
• HIV Antigens

Topics

• AIDS Vaccines (immunology)
• Cameroon (epidemiology)
• HIV Antibodies (blood, immunology)
• HIV Antigens (immunology)
• HIV Infections (epidemiology, immunology, prevention & control, virology)
• HIV-1
• Humans
• Multivariate Analysis
• Viral Load